Please login to the form below

Not currently logged in
Email:
Password:

Janssen/Jubilant alliance

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience.

The alliance, which will see Jubliant develop preclinical drug clients for Janssen to develop and commercialise, is set to last at least three years.

Jubilant is to receive research funding and is eligible for future milestones and royalties depending on the success of drug candidates.

Financial terms were not disclosed.

"The collaboration will utilise Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres," said Sri Mosur, CEO and president, global drug discovery and development, Jubilant.

"We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."

28th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...